JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

MeSH: dopaminové látky-aplikace a dávkování

10 záznamů v Články Filtry

Článek

Trial of Deferiprone in Parkinson's Disease

Devos, David
Autor Devos, David From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Labreuche, Julien
Autor Labreuche, Julien From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Rascol, Olivier
Autor Rascol, Olivier From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Corvol, Jean-Christophe
Autor Corvol, Jean-Christophe From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Duhamel, Alain
Autor Duhamel, Alain From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Guyon Delannoy, Pauline
Autor Guyon Delannoy, Pauline From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Poewe, Werner
Autor Poewe, Werner From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Compta, Yaroslau
Autor Compta, Yaroslau From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Pavese, Nicola
Autor Pavese, Nicola From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)
Růžička, Evžen
Autor Růžička, Evžen From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.) Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.) Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.) the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.) Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.) Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.) and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.)

The New England journal of medicine. 2022 ; 387 (22) : 2045-2055. [pub] 2022Dec01

N Engl J Med
ISSN 1533-4406
Medvik
Zdroj

BACKGROUND: Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson's disease, but its effects on disease progression are unclear. METHODS: We conducted a multicenter, phase 2, randomized, double-blind trial involving participants with newly diagnosed Parkinson's disease who had never received levodopa. Participants were assigned (in a 1:1 ratio) to receive oral deferiprone at a dose of 15 mg per kilogram of body weight twice daily or matched placebo for 36 weeks. Dopaminergic therapy was withheld unless deemed necessary for symptom control. The primary outcome was the change in the total score on the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS; range, 0 to 260, with higher scores indicating more severe impairment) at 36 weeks. Secondary and exploratory clinical outcomes at up to 40 weeks included measures of motor and nonmotor disability. Brain iron content measured with the use of magnetic resonance imaging was also an exploratory outcome. RESULTS: A total of 372 participants were enrolled; 186 were assigned to receive deferiprone and 186 to receive placebo. Progression of symptoms led to the initiation of dopaminergic therapy in 22.0% of the participants in the deferiprone group and 2.7% of those in the placebo group. The mean MDS-UPDRS total score at baseline was 34.3 in the deferiprone group and 33.2 in the placebo group and increased (worsened) by 15.6 points and 6.3 points, respectively (difference, 9.3 points; 95% confidence interval, 6.3 to 12.2; P<0.001). Nigrostriatal iron content decreased more in the deferiprone group than in the placebo group. The main serious adverse events with deferiprone were agranulocytosis in 2 participants and neutropenia in 3 participants. CONCLUSIONS: In participants with early Parkinson's disease who had never received levodopa and in whom treatment with dopaminergic medications was not planned, deferiprone was associated with worse scores in measures of parkinsonism than those with placebo over a period of 36 weeks. (Funded by the European Union Horizon 2020 program; FAIRPARK-II ClinicalTrials.gov number, NCT02655315.).

Článek

Memantine and Its Combination with Acetylcholinesterase Inhibitors in Pharmacological Pretreatment of Soman Poisoning in Mice

Neurotoxicity research. 2021 ; 39 (5) : 1487-1494. [pub] 20210722

Neurotox Res
ISSN 1476-3524
Medvik
Zdroj

Nerve agents pose a real threat to both the military and civil populations, but the current treatment of the poisoning is unsatisfactory. Thus, we studied the efficacy of prophylactic use of memantine alone or in combination with clinically used reversible acetylcholinesterase inhibitors (pyridostigmine, donepezil, rivastigmine) against soman. In addition, we tested their influence on post-exposure therapy consisting of atropine and asoxime. Pyridostigmine alone failed to decrease the acute toxicity of soman. But all clinically used acetylcholinesterase inhibitors administered alone reduced the acute toxicity, with donepezil showing the best efficacy. The combination of memantine with reversible acetylcholinesterase inhibitors attenuated soman acute toxicity significantly. The pretreatment administered alone or in combinations influenced the efficacy of post-exposure treatment in a similar fashion: (i) pyridostigmine or memantine alone did not affect the antidotal treatment, (ii) centrally acting reversible acetylcholinesterase inhibitors alone increased the antidotal treatment slightly, (iii) combination of memantine with reversible acetylcholinesterase inhibitors increased the antidotal treatment more markedly. In conclusion, memantine alone failed to decrease the acute toxicity of soman or increase post-exposure antidotal treatment efficacy. The combination of memantine with donepezil significantly increased post-exposure effectiveness (together 5.12, pretreatment alone 1.72). Both drugs, when applied together, mitigate soman toxicity and boost post-exposure treatment.

MeSH
acetylcholinesterasa metabolismus MeSH
antiparkinsonika aplikace a dávkování MeSH
cholinesterasové inhibitory aplikace a dávkování toxicita MeSH
donepezil aplikace a dávkování MeSH
dopaminové látky aplikace a dávkování MeSH
kombinovaná farmakoterapie MeSH
memantin aplikace a dávkování MeSH
myši MeSH
preexpoziční profylaxe metody MeSH
soman toxicita MeSH
zvířata MeSH
Check Tag
mužské pohlaví MeSH
myši MeSH
zvířata MeSH
Publikační typ
časopisecké články MeSH

Článek

The world journal of biological psychiatry. 2015 ; 16 (7) : 521-35. [pub] 20151007

World J Biol Psychiatry
ISSN 1814-1412
Medvik
Zdroj

OBJECTIVES: The self-medication hypothesis assumes that symptoms related to potential monoaminergic deficits in depression may be relieved by drug abuse. The aim of this study was to elucidate the neurotransmitter changes in a rat model of depression by measuring their levels in the nucleus accumbens shell, which is typically involved in the drug of abuse acquisition mechanism. METHODS: Depression was modelled by the olfactory bulbectomy (OBX) in Wistar male rats. In vivo microdialysis was performed, starting from the baseline and following after a single methamphetamine injection and behaviour was monitored. The determination of neurotransmitters and their metabolites was performed by high-performance liquid chromatography combined with mass spectrometry. RESULTS: OBX animals had lower basal levels of dopamine and serotonin and their metabolites. However, γ-aminobutyric acid (GABA) and glutamate levels were increased. The methamphetamine injection induced stronger dopamine and serotonin release in the OBX rats and lower release of glutamate in comparison with sham-operated rats; GABA levels did not differ significantly. CONCLUSIONS: This study provides an evidence of mesolimbic neurotransmitter changes in the rat model of depression which may elucidate mechanisms underlying intravenous self-administration studies in which OBX rats were demonstrated to have higher drug intake in comparison to intact controls.

MeSH
autoaplikace MeSH
deprese farmakoterapie MeSH
dopamin metabolismus MeSH
dopaminové látky aplikace a dávkování MeSH
GABA metabolismus MeSH
krysa rodu rattus MeSH
kyselina glutamová metabolismus MeSH
methamfetamin aplikace a dávkování MeSH
mikrodialýza MeSH
modely nemocí na zvířatech MeSH
neurotransmiterové látky metabolismus MeSH
nucleus accumbens patofyziologie MeSH
odměna * MeSH
potkani Wistar MeSH
serotonin metabolismus MeSH
zvířata MeSH
Check Tag
krysa rodu rattus MeSH
mužské pohlaví MeSH
zvířata MeSH
Publikační typ
časopisecké články MeSH
práce podpořená grantem MeSH

Článek

Dlouhodobá terapie intraduodenální levodopou – kazuistiky tří pacientů
[Long-term treatment with intraduodenal levodopa – case report of three patients]

Neurologie pro praxi. 2014 ; 15 (3) : 155-157.

Neurol. praxi
ISSN 1213-1814
Medvik
Zdroj

Předkládáme kazuistiky tří pacientů s pokročilou Parkinsonovou nemocí (PN) léčených dlouhodobě intraduodenální levodopou – Duodopa. Duodopa umožňuje kontinuální podávání dopaminergní léčby, které je indikováno u pacientů s pozdními hybnými komplikacemi. Zavedení sondy přímo do jejuna a snadná úprava dávky vedou ke stabilizaci plazmatických hladin levodopy a výraznému pozitivnímu ovlivnění motorického stavu pacientů s PN. Tato invazivní metoda má významné místo v terapii pozdních hybných komplikací PN.

We present case reports of three patients with Parkinson‘s disease (PD) treated with intradudodenal levodopa – Duodopa. Duodopa enables continuous administration of dopaminergicv treatment indicated for patients with late motor complications. Administration of levodopa into the jejunal part of duodenum and easy dose setting leads to stable plasma levels of levodopa and an improvement of motor state of patients with PD. This invasive procedure plays an important role in therapy of late motor complications of PD.

Klíčová slova
Duodopa,
MeSH
antiparkinsonika aplikace a dávkování škodlivé účinky terapeutické užití MeSH
dopaminové látky aplikace a dávkování terapeutické užití MeSH
infuzní pumpy * MeSH
levodopa * aplikace a dávkování terapeutické užití MeSH
lidé středního věku MeSH
lidé MeSH
neurologické manifestace MeSH
Parkinsonova nemoc * etiologie farmakoterapie komplikace MeSH
progrese nemoci MeSH
senioři nad 80 let MeSH
senioři MeSH
Check Tag
lidé středního věku MeSH
lidé MeSH
mužské pohlaví MeSH
senioři nad 80 let MeSH
senioři MeSH
Publikační typ
kazuistiky MeSH

Článek

Zlepšení kvality života v pokročilé fázi Parkinsonovy nemoci intraduodenálními infuzemi levodopy
[Improving quality of life in advanced stage Parkinson's disease with intraduodenal levodopa infusions]

Neurologie pro praxi. 2014 ; 15 (5) : 278-280.

ISSN 1213-1814
Medvik
Zdroj

Pokročilé stadium idiopatické Parkinsonovy nemoci je charakterizováno především motorickými fluktuacemi. Tyto často nelze zvládnout ani za využití všech možností perorální farmakoterapie. Jednou z možností řešení jsou pak kontinuální intestinální infuze L-DOPA, které zajišťují stabilnější plazmatickou koncentraci L-DOPA. Intestinální gel obsahující L-DOPA je aplikován pomocí přenosné pumpy a sondou zavedené cestou perkutánní endoskopické gastrostomie přímo do terminální části duodena, kde je L-DOPA resorbována. Efekt této terapie a její přínos ke zlepšení motorických fluktuací, a tím také kvality života dokumentuje následující kazuistika 70letého muže trpícího Parkinsonovou nemocí v pokročilém stupni.

Advanced stage of idiopathic Parkinson's disease is characterized particularly by motor fluctuations. These often cannot be controlled even when all the options of oral pharmacotherapy are utilized. One of the management options is then to use continuous intestinal L-DOPA infusions providing a more stable plasma concentration of L-DOPA. L-DOPA intestinal gel is administered by means of a portable pump and a tube that is inserted via percutaneous endoscopic gastrostomy directly into the terminal part of the duodenum where L-DOPA is resorbed. The effect of this treatment and its benefit in terms of improving motor fluctuations and thus the quality of life is documented by the present case report of a 70-year-old man with advanced stage Parkinson's disease.

Klíčová slova
intestinální infuze L-DOPA, perkutánní endoskopická gastrostomie (PEG),
MeSH
adherence pacienta MeSH
antiparkinsonika aplikace a dávkování terapeutické užití MeSH
dopaminové látky aplikace a dávkování terapeutické užití MeSH
duodenum MeSH
dyskineze farmakoterapie MeSH
gastrointestinální endoskopie MeSH
gastrostomie MeSH
gely aplikace a dávkování terapeutické užití MeSH
infuzní pumpy MeSH
jejunum MeSH
levodopa * aplikace a dávkování terapeutické užití MeSH
lidé MeSH
miniinvazivní chirurgické výkony MeSH
parenterální infuze * metody MeSH
Parkinsonova nemoc * farmakoterapie MeSH
pohybové poruchy farmakoterapie MeSH
senioři MeSH
výběr pacientů MeSH
Check Tag
lidé MeSH
mužské pohlaví MeSH
senioři MeSH
Publikační typ
kazuistiky MeSH

Článek

Schlechte, J. A.: Aktualizace poznatků v oblasti hypofýzy v roce 2010

Kršek, Michal
Autor Autorita

Revue endokrinologie. 2012 ; 15 (1) : 7-12.

Rev. Endokrin.
ISSN 1801-6413
Medvik
Zdroj

Článek

Deniban v léčbě dystymie
[Deniban in the treatment of dysthymia]

Češková, Eva, 1946-
Autor Autorita ORCID

Česká a slovenská psychiatrie. 2007 ; 103 (2) : 73-79.

ISSN 1212-0383
Medvik
Zdroj

Dystymie je chronická mírná deprese, která snižuje kvalitu života. V poslední době se ukazuje, že úspěšné v léčbě deprese mohou být i dopaminergně působící látky. Z těchto je v pro léčbu dystymie v ČR registrován amisulprid v malých dávkách (preparát Deniban). S Denibanem byla provedena u dystymie prospektivní, otevřená, observační studie. Zařazeno bylo 510 nemocných, 90 % léčených dokončilo čtyřměsíční studii a 87 % nadále hodlalo s léčbou pokračovat. Již po prvním týdnu došlo k signifikantnímu snížení symptomatologie (hodnoceno dle MADRS) a tento trend byl udržen do konce studie. U 83,4 % došlo k velmi výraznému nebo značnému zlepšení. Deniban byl dobře snášen, vedlejší účinky se vyskytly u 59/510 (11,57 %) léčených, nejčastěji se vyskytovaly: galaktorea u 11/510 (2,16 %), bolest hlavy u 7/510 (1,37 %), ospalost u 5/510 (0,98 %), nauzea a xerostomie 5/510 (0,98 %) a mastody-nie u 4/510 (0,78 %). Tyto výsledky ukazují, že dopaminergní látky mohou být lékem volby u dystymie.

Dysthymia is a chronic, mild depression with an impact on the quality of life. Recently it has been shown that dopaminergic agents could be successful in the treatment of depression. Amisulpride which has in low doses (Deniban) dopaminergic activity is registered for the treatment of dysthymia in Czech republic. A prospective, open observational study of dysthymia treatment with Deniban has been performed. Totally 510 patients suffering from dysthymia were included. Ninety % of the patients finished all 4 months of the study and 87% of the treated wanted to continue with Deniban. A significant reduction of symptoms (according to MADRS) has been observed after one week and this trend has continued till the end of the study. In 83.4% of patients there was a marked improvement. Deniban subjects was well tolerated, side effects were found in 59/510 (11.57%) of the treated. The most frequently observed symptoms were galactorrhea in 11/510 (2.16%), headache in 7/510 (1.37%), somnolence in 5/510(0.98%), both nausea and xerostomia in 5/510 (0.98) and mastodynia in 4/510 (0.78%). These results show that dopaminergic drugs may be drugs of choice in dysthymia.

Klíčová slova
Deniban,
MeSH
antipsychotika aplikace a dávkování škodlivé účinky terapeutické užití MeSH
dopaminové látky aplikace a dávkování škodlivé účinky terapeutické užití MeSH
dystymie farmakoterapie MeSH
interpretace statistických dat MeSH
lidé MeSH
příznaky a symptomy MeSH
prospektivní studie MeSH
výsledek terapie MeSH
Check Tag
lidé MeSH

Článek

Parkinsonova nemoc, antiparkinsonika a kognitivní funkce

Rektorová, Irena, 1969-
Autor Autorita

Remedia. 2005 ; 15 (6) : 528-533.

ISSN 0862-8947
Medvik
Zdroj

Parkinsonova nemoc (PN) je neuro-degenerativní onemocnění postihující 100 až 150 pacientů na 100 000 obyvatel. Onemocní asi 1 % osob starších 60 let.

Článek

Zástava laktace po potratu ve 2. trimestru jednorázovým podáním cabergolinu ve srovnání s desetidenním podáváním terguridu
[Arrest of lactation after abortion during the second trimester of pregnancy by administration of a single dose of cabergoline as compared with ten-day terguride administration]

Česká gynekologie. 2003 ; Roč. 68 (č. 1) : s. 46-50.

ISSN 1210-7832
Medvik
Zdroj

Cíl studie: Cílem práce bylo porovnat účinnost a toleranci jednorázového podání 1 mg cabergolinua desetidenního podání 1,5 mg terguridu rozděleného do tří dávek po osmi hodinách v indikacizástavy laktace po potratu ve II. trimestru.Typ studie: Prospektivní klinická studie.Název a sídlo pracoviště: Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze, Apolinářská18, Praha 2.Metodika: V období od ledna do října 2000 byl 41 pacientkám po indukovaném potratu ve II.trimestru podáván tergurid 0,5 mg po osmi hodinách po dobu 10 dní. V následujícím období odlistopadu 2000 do září 2001 byl 43 pacientkám podáván cabergolin v jednorázové dávce 1 mg do 12hodin po potratu. Během hospitalizace byly pacientky denně dotazovány na subjektivní hodnoceníúčinku léčby (závrať, palpitace, cefalea, nauzea, zvracení, bolest břicha, ospalost, sekrecez prsu, napětí v prsech) a lékařem objektivně hodnocena úspěšnost léčby. Po 21 dnech po potratubyly pacientky telefonicky dotázány na subjektivní i objektivní účinek léčby. Statistické hodnoceníbylo provedeno Fisherovým exaktním dvoustranným testem.Výsledky: Skupina „cabergolin” oproti skupině „tergurid” vykazuje významně nižší výskyt nežádoucíchúčinků (p

Objective: The objective of the work was to compare the effectiveness and tolerance of a singleadministration of 1 mg cabergoline and 10-day administration of 1.5 mg terguride divided intothree doses after 8-hour intervals, in the indication of arrest of lactation after an abortion duringthe second trimester.Type of study: Prospective clinical study.Name and place of department: Gynaecological and Obstetric Clinic. First Medical Faculty CharlesUniversity and General Faculty Hospital Prague, Apolinářská 18, Prague 2. Method: During the period between January and October 2000 to 41 patients after abortioninduced during the 2nd trimester terguride, 0.5 mg after 8-hour intervals, was administered fora 10-day period. During the subsequent period from November 2000 to September 2001 to 43patients cabergoline was administered in a single dose within 12 hours after the abortion. Duringhospitalization the patients were asked daily for their subjective evaluation of the effect of treatment(vertigo, palpitations, headache, nausea, vomiting, abdominal pain, sleepiness, secretionfrom the breast, tension in the breasts) and the doctor evaluated the success of treatment objectively.Within 21 days after the abortion the patients were addressed over the phone on subjectiveand objective effects of treatment. For statistical evaluation Fisher’s exact bilateral test was used.Results: The „cabergoline” group displayed, as compared with the „terguride” group, significantlyfewer undesirable effects (p

MeSH
antagonisté serotoninu aplikace a dávkování škodlivé účinky terapeutické užití MeSH
dopaminové látky aplikace a dávkování škodlivé účinky terapeutické užití MeSH
dospělí MeSH
druhý trimestr těhotenství MeSH
indukovaný potrat MeSH
laktace účinky léků MeSH
lidé MeSH
mladiství MeSH
Check Tag
dospělí MeSH
lidé MeSH
mladiství MeSH
ženské pohlaví MeSH
Publikační typ
přehledy MeSH

Článek

Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease

Movement disorders. 2000 ; Roč. 15 (č. 4) : s. 734-735.

ISSN 0885-3185
Medvik
Zdroj

Kolekce

Publikováno

Filtry

Filtry

* Zobrazit nápovědu

* Zobrazit nápovědu

Upřesnit dle MeSH